NCT04569877View on ClinicalTrials.gov

GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

June 21, 2022

Study Completion Date

September 20, 2022

Conditions
Severe Acute Respiratory Syndrome (SARS) PneumoniaCOVID-19 Pneumonia
Interventions
DRUG

Molgramostim nebuliser solution

300μg molgramostim nebuliser solution nebulised seven times within 7 days via rapid nebuliser system

OTHER

Placebo nebuliser solution

Placebo nebulised seven times within 7 days via rapid nebuliser system

Trial Locations (9)

30625

Medizinische Hochschule Hannover, Hanover

34376

Lungenfachklinik Immenhausen, Immenhausen

35392

Universitätsklinikum Giessen und Marburg GmbH, Standort Giessen, Giessen

45147

Universitätsklinikum Essen, Essen

60488

Krankenhaus Nordwest GmbH, Frankfurt am Main

60590

Universitätsklinikum Frankfurt, Frankfurt am Main

63069

Sana Klinikum Offenbach, Offenbach

69126

Universitätsklinikum Heidelberg, Heidelberg

01307

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

All Listed Sponsors
lead

University of Giessen

OTHER

NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter